RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide First Quarter 2022 Update on Medical Aesthetic Launch
23 mars 2022 16h45 HE
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will...
RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022
09 mars 2022 16h30 HE
|
RVL Pharmaceuticals plc
BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief...
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
19 janv. 2022 11h38 HE
|
Osmotica Holdings US LLC; RVL Pharmaceuticals plc
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25...
Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
19 janv. 2022 06h50 HE
|
Osmotica Holdings US LLC; RVL Pharmaceuticals plc
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25...
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
18 janv. 2022 06h50 HE
|
Osmotica Holdings US LLC
-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper -- ...
Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
06 janv. 2022 08h55 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian...
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
20 déc. 2021 16h05 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian...
Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update
15 nov. 2021 16h05 HE
|
Osmotica Holdings US LLC
Third quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales Expansion of Upneeq launch continues with introduction of Direct Dispense program in eyecare and...
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
15 nov. 2021 06h50 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian...
Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021
11 nov. 2021 19h30 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company...